Olema Pharmaceuticals Inc (OLMA)

Apr 8, 2025, 4:25 PM EDT - 11 days ago

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Apr 2, 2025, 4:30 PM EDT - 17 days ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 25, 2025, 4:31 PM EDT - 25 days ago

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Mar 18, 2025, 4:01 PM EDT - 4 weeks ago

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 7:00 AM EST - 2 months ago

Olema Oncology Appoints Shawnte M. Mitchell, J.D.

Feb 3, 2025, 4:30 PM EST - 2 months ago

Olema Oncology to Participate in Upcoming Investor Conferences

Jan 2, 2025, 7:00 AM EST - 3 months ago

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 7:46 AM EST - 4 months ago

Top 3 Health Care Stocks That May Explode In Q4

MODV SLN

Dec 10, 2024, 7:00 AM EST - 4 months ago

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Dec 9, 2024, 7:00 AM EST - 4 months ago

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Nov 25, 2024, 5:30 PM EST - 5 months ago

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Nov 12, 2024, 4:01 PM EST - 5 months ago

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 23, 2024, 7:00 AM EDT - 6 months ago

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Oct 9, 2024, 7:00 AM EDT - 6 months ago

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 21, 2024, 7:00 AM EDT - 8 months ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 4:02 PM EDT - 9 months ago

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 28, 2024, 7:03 AM EDT - 11 months ago

Olema Oncology to Participate in Upcoming Investor Conferences in June

May 15, 2024, 7:01 AM EDT - 1 year ago

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

May 8, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

May 1, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in May

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Mar 11, 2024, 4:03 PM EDT - 1 year ago

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 7:03 AM EST - 1 year ago

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Jan 8, 2024, 8:12 AM EST - 1 year ago

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Jan 3, 2024, 8:29 AM EST - 1 year ago

Olema Pharmaceuticals: Oral SERD Developer With Interesting Data

Jan 2, 2024, 4:01 PM EST - 1 year ago

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 12:27 PM EST - 1 year ago

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Nov 28, 2023, 5:10 PM EST - 1 year ago

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

Nov 28, 2023, 11:52 AM EST - 1 year ago

Olema Pharmaceuticals: Advancing On Multiple Fronts

Nov 7, 2023, 4:02 PM EST - 1 year ago

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 1, 2023, 4:27 PM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in November

Oct 22, 2023, 2:55 AM EDT - 1 year ago

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Oct 17, 2023, 7:01 AM EDT - 1 year ago

Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

Oct 16, 2023, 7:02 AM EDT - 1 year ago

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

Oct 12, 2023, 7:01 AM EDT - 1 year ago

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

Sep 20, 2023, 7:29 AM EDT - 1 year ago

Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 3:20 PM EDT - 1 year ago

Olema: Two-Pronged Approach To Treat Breast Cancer Patients

Sep 5, 2023, 7:30 AM EDT - 1 year ago

Olema Oncology Announces Combined Financing for Up to $180 Million

Aug 8, 2023, 4:03 PM EDT - 1 year ago

Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 1, 2023, 8:00 AM EDT - 1 year ago

Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference

May 30, 2023, 4:30 PM EDT - 2 years ago

Olema Oncology to Present at the 2023 Jefferies Healthcare Conference

May 19, 2023, 4:30 PM EDT - 2 years ago

Olema Oncology: Best Contrarian Oncology Play For 2023

May 11, 2023, 8:43 AM EDT - 2 years ago

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

May 9, 2023, 4:01 PM EDT - 2 years ago

Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 8, 2023, 7:06 AM EDT - 2 years ago

Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress

Apr 13, 2023, 4:30 PM EDT - 2 years ago

Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

Mar 9, 2023, 4:00 PM EST - 2 years ago

Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update

Mar 2, 2023, 4:05 PM EST - 2 years ago

Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference

Feb 21, 2023, 4:30 PM EST - 2 years ago

Olema Oncology to Participate at Upcoming Investor Conferences